Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females aged 18-65 years, inclusive~2. ≥10 cigarettes per day with no period of abstinence longer than 3 months in the past year and who are motivated to quit smoking~3. Able to give signed informed consent~4. Eligible female patients will be:~   1. non-pregnant~  2. non-lactating~  3. agree to use an acceptable method of effective contraception during the study~5. Eligible male patients agree to use contraception when sexually active with a female partner who is not using an acceptable method of birth control~6. Body weight of ≥50 kg (110 pounds), inclusive~7. Considered to be in stable health in the opinion of the investigator~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. Prior or current use of lorcaserin HCl~2. Prior participation in any study of a nicotine vaccination~3. Use of other therapies for smoking cessation is not allowed within 3 months of screening through study exit~4. Use of tobacco products other than cigarettes~5. Prior use of fenfluramine or dexfenfluramine~6. Serious or unstable medical condition or clinically significant new illness within the 6 months prior to screening~7. Previous participation in any clinical study within 6 weeks prior to the screening visit~8. History of severe allergies, severe drug or excipient allergy or hypersensitivity~9. History of significant cardiovascular condition~10. History of other significant medical conditions~11. Significant risk of suicide~12. Anticipated use of any agents that are associated with valvulopathy and/or pulmonary hypertension~13. Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~14. Recent history of alcohol or drug/solvent abuse~15. Concurrent participation in the study by more than one member of the same household~16. Not suitable to participate in the study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- APD356 10 mg b.i.d. (Type: EXPERIMENTAL): APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
- APD356 10 mg q.d. (Type: EXPERIMENTAL): APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
- Placebo 10 mg b.i.d (Type: PLACEBO_COMPARATOR): Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).